July 12, 2023

To	To
Listing Department, **NATIONAL STOCK EXCHANGE OF INDIA LIMITED** Exchange Plaza, Bandra Kurla Complex, Bandra (E), **MUMBAI -400 051** **Company Code No. AUROPHARMA**	The Corporate Relations Department **BSE LIMITED** Phiroz Jeejeebhoy Towers, 25th floor, Dalal Street, **MUMBAI -400 001** **Company Code No. 524804**

Dear Sir/ Madam,

Sub: Press Release – APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.

We enclose a copy of the Press Release that is being issued by the Company in connection with USFDA approval received by APL Healthcare Limited, a wholly owned subsidiary of the Company for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.

Please take the information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.07.12 15:46:48 +05'30'

B. Adi Reddy
Company Secretary

Encl: as above

Hyderabad, India, July 12, 2023

APL Healthcare receives USFDA Approval for Sevelamer Hydrochloride Tablets 400 mg and 800 mg.

Aurobindo Pharma Limited is pleased to announce that it's wholly owned subsidiary company, APL Healthcare Limited, has received a final approval from the US Food & Drug Administration (USFDA) to manufacture and market Sevelamer Hydrochloride Tablets 400 mg and 800 mg, Sevelamer Hydrochloride Tablets 400 mg and 800 mg, to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Renagel Tablets, 400 mg and 800 mg, of Genzyme Corporation.

The approved product has an estimated market size of around US$ 37 million for the twelve months ending May 2023, according to IQVIA.

This is the 57th ANDA approved out of APL Healthcare Unit IV formulation facility, used for manufacturing oral products. Aurobindo now has a total of 463 ANDA approvals (437 Final approvals and 26 tentative approvals) from USFDA.

Sevelamer Hydrochloride Tablets 400 mg and 800 mg is indicated for the control of serum phosphorus in patients with chronic kidney disease (CKD) on dialysis.

About Aurobindo Pharma Limited

Aurobindo Pharma Limited (www.aurobindo.com), (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and commercializes a wide range of generic pharmaceuticals, branded specialty pharmaceuticals and active pharmaceutical ingredients globally in over 150 countries.

The company has 25 manufacturing and packaging facilities that are approved by leading regulatory agencies including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, Brazil ANVISA. The company's robust product portfolio is spread over 7 major therapeutic/product areas encompassing CNS, Anti-Retroviral, CVS, Antibiotics, Gastroenterological, Anti-Diabetics and Anti-Allergic, supported by a strong R&D set-up.

To know more, please log on to www.aurobindo.com

For further information or queries, please contact:

Soumen Biswas | Deepti Thakur
Investor Relations | Corporate Communications
Phone: +91 40 66725401 / 66725000
Email: ir@aurobindo.com

Disclaimer:

This press release contains statements that may constitute “forward looking statements” including and without limitation, statements relating to product characteristics and uses, sales potential and target dates for product launch, implementation of strategic initiatives, and other statements relating to our future business developments and economic performance. While these forward-looking statements represent our judgment and future expectations concerning the development of our business, a number of risks, uncertainties and other factors could cause actual developments and results to differ materially from our expectations. The company undertakes no obligation to publicly revise any forward-looking statements to reflect future events or circumstances and will not be held liable for any use of this information.

ADIREDDY BADDIGAM
Digitally signed by ADIREDDY BADDIGAM
Date: 2023.07.12 15:47:16 +05'30'